Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vanessa Correa

Pulmonary Disease Torrance, CA Medical Doctor

NPI 1174960504 CMS profile 1395125

1000 W Carson Street Box 400, Torrance, CA 90509

Open in the dashboard

General payments

$1,862

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vanessa Correa of Torrance, CA is reported in the CMS Open Payments database as having received $1,862 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $459 15
2024 General $37 1
2023 General $24 1
2022 General $491 21
2021 General $490 18
2020 General $52 2
2019 General $309 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vanessa Correa
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Vanessa Correa were reported at $459. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Vanessa Correa Pulmonary Disease median Middle half National median
2019 $309 $377 $109–$1,340 $163
2020 $52 $230 $56–$907 $114
2021 $490 $269 $68–$1,072 $132
2022 $491 $390 $100–$1,457 $149
2023 $24 $419 $114–$1,659 $160
2024 $37 $476 $123–$1,818 $164
2025 $459 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $827 30 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $307 14 payments
  3. AstraZeneca Pharmaceuticals LP $240 7 payments
  4. Pfizer Inc. $151 4 payments
  5. Genentech USA, Inc. $100 1 payment
  6. Mylan Specialty L.P. $58 2 payments
  7. Medtronic, Inc. $45 1 payment
  8. Genzyme Corporation $39 2 payments
  9. Abiomed $37 1 payment
  10. Amgen Inc. $34 1 payment
  11. Other $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,577 60 payments
  2. Consulting Fee $185 3 payments
  3. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. NUCALA $492 15 payments
  2. OFEV $330 10 payments
  3. TRELEGY ELLIPTA $314 14 payments
  4. BREZTRI $189 4 payments
  5. ELIQUIS $151 4 payments
  6. STIOLTO RESPIMAT $142 9 payments
  7. SPIRIVA RESPIMAT $114 7 payments
  8. Esbriet $100 1 payment
  9. Yupelri $58 2 payments
  10. FASENRA $51 3 payments
  11. Other $241 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,267

Median for Pulmonary Disease: 936

Drug cost

$692,391

Median for Pulmonary Disease: $487,987

Branded share of claims

61.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 274 $219,551
Ofev Nintedanib Esylate Brand 12 $155,763
Breo Ellipta Fluticasone/Vilanterol Brand 166 $79,438
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 89 $58,619
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 84 $51,841
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 36 $23,470
Wixela Inhub Fluticasone Propion/Salmeterol Brand 129 $19,210
Spiriva Respimat Tiotropium Bromide Brand 24 $17,219
Atrovent Hfa Ipratropium Bromide Brand 32 $15,684
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 74 $12,099

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$13,430

Of which drugs: $2,744

Medicare patients

52

Average age 74

Services billed

183

29 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 37%
COPD 37%
Chronic kidney disease 35%
Ischemic heart disease 33%
Depression 25%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record